Structure Therapeutics (NASDAQ:GPCR) Shares Down 7.5% – Should You Sell?

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR)’s share price was down 7.5% during trading on Wednesday . The company traded as low as $52.10 and last traded at $51.9140. Approximately 216,549 shares traded hands during mid-day trading, a decline of 79% from the average daily volume of 1,034,382 shares. The stock had previously closed at $56.15.

Analyst Upgrades and Downgrades

GPCR has been the subject of several research reports. Citigroup reissued an “outperform” rating on shares of Structure Therapeutics in a research report on Friday, December 12th. Wall Street Zen raised shares of Structure Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Citizens Jmp lowered their target price on shares of Structure Therapeutics from $120.00 to $113.00 and set a “market outperform” rating on the stock in a report on Friday, February 27th. Jefferies Financial Group set a $125.00 price target on shares of Structure Therapeutics and gave the company a “buy” rating in a research report on Thursday, December 11th. Finally, Stifel Nicolaus lifted their price target on Structure Therapeutics from $50.00 to $90.00 and gave the company a “buy” rating in a research note on Monday, December 8th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $110.00.

Structure Therapeutics Price Performance

The stock has a fifty day moving average of $73.19 and a 200 day moving average of $50.24. The firm has a market capitalization of $3.68 billion, a P/E ratio of -65.80 and a beta of -1.80.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.14). Equities analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current fiscal year.

Institutional Trading of Structure Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Osaic Holdings Inc. increased its stake in shares of Structure Therapeutics by 101.9% during the 2nd quarter. Osaic Holdings Inc. now owns 63,362 shares of the company’s stock worth $1,314,000 after purchasing an additional 31,972 shares during the last quarter. Aberdeen Group plc increased its position in Structure Therapeutics by 46.1% in the third quarter. Aberdeen Group plc now owns 586,869 shares of the company’s stock worth $16,432,000 after buying an additional 185,245 shares during the last quarter. Birchview Capital LP bought a new stake in shares of Structure Therapeutics in the second quarter valued at $747,000. Jefferies Financial Group Inc. purchased a new position in shares of Structure Therapeutics during the 3rd quarter valued at $4,770,000. Finally, Private Capital Advisors Inc. bought a new position in shares of Structure Therapeutics during the 3rd quarter worth $1,545,000. Institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.